larg cap biotech could get interest
initi buy pt
initi coverag buy rate
price target time biotechnolog sector caught
crosshair intens
innov recept market therapeut
crowd see compani well posit histori
invest imag approach hard-nos busi cultur
focu neurosci cash-cow stabl ms drug
els market cap reach
tough grow explos chang world hcv treatment
work bring high activ oral drug ms space
convers develop antibodi reduc cholesterol seem less
viabl path light aducanumab look like uniqu asset
aso seem say treatment sma gotten crowd
despit miracl antisens oligo aso spinraza
aav-gen therapi type sma children walk
overal expect sma lead way treatment similar
diseas gene therapi take shot correct follow
normal approach like aso sens like
biogen broad aso deal ioni rate
ms project ms busi provid
cash fund next five year expect mostli smallish
deal biogen prowess make differ larger
deal expect new technolog focu seem
compani behind gene therapi radar novel
uptak technolog like use denali
valuat aducanumab clearli someth recent
readout eiasi antibodi beyond strang clinical-
trial move seem reinforc stori expect excit
build aducanumab stori near first readout
stock well pt base dcf methodolog
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
imag everyth drug develop neurosci complex get
addit good anim model lack mani import diseas princip due
fact make delet mice mimic diseas requir solid understand
diseas mechan forefront develop imag
technolog help identifi treatment someth molecular even
link actual clinic benefit may still theoret aducanumab good
exampl took extra imag step ensur patient ad
synergi trial actual a-beta plaqu drug design remov
recent imag use resurrect remyelin program find patient
drug activ make sens
 need jump start lead compani neurolog space
seem significantli behind develop gene therapi like novarti
nv rate voyag buy therapeut get mab
protein across blood brain barrier like denali approach situat may
contradict previou paragraph simpli suggest spend time
side may eventu partner potenti disrupt technolog
addit matur compani choos enter area mean know
better howev given clinic hold first aav-bas gene therapi
may suggest catch make sens
banucanumab what name pair anti-ab antibodi probabl
repres largest commerci opportun collect biotech pipelin
eye activ aducanumab show pretti clear cognit effect crystal clear
plaqu remov characterist extens synergi trial pivot trial enrol
know around complet gigant trial
adapt design enrol five time mani patient arm rel other
base earli adcom score enrol result seem suggest activ
subsequ efficaci data clearli taint decis enrol higher risk
patient outsid placebo arm howev limit data avail least suggest
higher risk patient get diseas earli dont progress rapidli
ruin trial
aducanumab success invit signific complet aducanumab program
read posit de-risk a-beta hypothesi like open
floodgat compet approach exampl improv deliveri antibodi
brain might greatli simplifi bbb-transport technolog denali
aav-bas approach voyag similarli a-beta bind format
beyond mab includ bind tau well along small molecul
approach design protect key structur nerv cell destruct bind
a-beta oligom approach would get signific shot arm
posit aducanumab readout includ easier time rais money possibl shot
abbrevi acceler approv pathway
tecfidera ms treatment landscap ms sale remark
resili sinc introduct ocrelizumab go forward think compani
could benefit overal trend effect treatment earli diseas
inflammatori process silent signific damag addit
copaxon gener share voic support low activ drug expect
diminish tecfidera like inherit mani patient along line
new tecfidera analog rate could make start fumar
class much easier lead reduc rate earli drop estim
tecfidera starter drop gi issu
ms competit get wors ocrelizumab celgen celg buy look like
excel drug compani figur ms space ocrelizumab could take
share ocrelizumab baggag cv monitor expect case
pml would big deal drug aim front line addit part
reason ocrelizumab effect mute royalti
receiv roch novarti second drug trial also seem
like take share high-efficaci categori without offset royalti
aso stay idea singl treatment replac correct damag
gene certainli seem prefer lifetim inject design modul
patient genet express normal state howev even gene therapi
work one shot approach littl control dose unknown durat
stroke two three four follow acquisit earlier year biogen
continu increas presenc stroke follow two program
field interest program look significantli de-risk base prior data
rework trial design start indic larg hemispher infarct
lhi probabl acut like lifesav activ econom return
could decent view second stroke drug clot buster
indic make babi seal hunt seem festiv howev compani
stand good place use imag identifi correct patient follow
drug activ search therapeut indic
biosimilar power platform alway seem sleepi
program tuck away becom meaning good time agreement
manufactur tysabri obscur psoriasi drug call space-ag project exon
skip deal fuse hemophilia factor antibodi fc domain good
exampl newest hole card seem biosimilar collabor
samsung rate biosimilar field seem rapidli devolv
compani like momenta rate grand eleg plan
realiz may game muscl good luck partner
three approv anti-tnfa therapi predict eventu sale million
franchis
biogen pipelin heavi trial ad ms
convent develop pipelin top graphic also line-
extens pipelin ms space lower graphic aducanumab ad
import pipelin therapeut follow complex stroke victim aso
pipelin ioni account larg number project rel
earli stage ms vumer tecfidera analog import program
exhibit pipelin ms line extens plan
next month anticip follow pipelin mileston
nda file fda head-to-head data
data hv
data al
data psp
data x-link retinoschisi
given differenti portfolio product product candid gener
lack directli compar peer util discount cash flow dcf analysi use
base-cas revenu assumpt project arriv dcf-
deriv price target per share use discount rate gordon
growth termin multipl modesti assum growth rate futur cash flow
feel appropri captur breadth collect uncertainti
surround early-stag pipelin furthermor probability-adjust project
revenu aducanumab respect
dcf valuat pv futur cash flow pv termin valu enterpris valu equival debt market valu share outstand per growthdiscount rate
risk invest thesi
establish drug develop commerci compani face
standard risk industri includ unexpect neg clinic readout
associ aducanumab develop program
regulatori uncertainti increas complex price-sensit commerci market
product
two big question perform stock outcom
trial aducanumab impact sma gene therapi
model aducanumab drug base sell price
annual line ms drug ascrib probabl
success aducanumab
spinraza model two flat quarter growth start
re-start conserv model attrit sale growth follow
market entri assum posit data
addit aso product noth explicitli model
ms busi follow manag guidanc flat sale two
year follow increas base princip launch
think patent protect tecfidera alreadi highli scrutin
pto note pretti low bar file ipr hope get
institut ground reason chanc one claim
might overthrown dont model gener competit
although think forward patent would nice addit
obstacl licens destroy interfer proceed
model success stroke program adopt price
point think penetr rel rapid real soc
lhi ascrib probabl success
aducanumab mg gorilla
monoclon antibodi aducanumab target toxic oligom a-
beta protein may repres largest commerci opportun biotechnolog
space said clear mab remov aggreg protein
plaqu typifi diseas remain less clear much clinic benefit
improv patient function molecular activ deliv patient addit
earli progress aducanumab need introduc
econom way identifi patient like benefit
therapeut expect expens
import earli safeti signal aducanumab imag
patient asymptomat aria treat noth amiss
aducanumab work els pipelin might work better
posit aducanumab valid plaqu remov biomark clinic
benefit allow subsequ drug shot acceler approv base
second a-beta mab collabor eisai
good aducanumab
program huge amount data mani question
good news mani question answer on-going
trial month treatment enrol complet juli trial
done earli extens studi done
one interest wrinkl trial addit patient earli due
observ higher expect variabl endpoint measur
overal program includ patient treatment effect
anyth like seen prime trial posit
exhibit trial engag emerg
aducanumab mid-term reason biogen
long expens goodby alzheim diseas ad common
neurodegen disord affect million peopl world-wide term
log goodby ad probabl rel long asymptomat phase term
prodrom follow onset mild cognit impair gener
progress deeper form dementia diseas character extracellular
amyloid plaqu within intracellular tangl second protein tau
exhibit solubl a-beta monom progress multimer form plaqu
unlik somewhat murki molecular mechan ramif societ
cost diseas clear peopl live
ad gener age popul expect doubl number
year slow progress patient progress like transit
per year bed long term care facil big opportun put
number togeth alzheim associ put current cost ad nearli
 forecast number grow
function discoveri aducanumab human-deriv antibodi target
amyloid- oligom believ drive neuron cell death
character alzheim diseas antibodi isol patient
appear progress unusu slowli ad symptom gener approach
isol protect antibodi rest reason firm scientif ground
aducanumab preferenti bind toxic solubl oligomer form ab
increasingli accept bad actor ad progress
word
aducanumab discrimin monom oligomer fibrillar aggreg
molecular properti consist current thought
discrimin
import antibodi distract sea harmless monom believ
case solanezumab never effect remov toxic oligom
argument still remain somewhat theoret rel import
plaqu vs tau tangl see briefli import origin
hypothes base patient early-onset genet form ad mani
patient found mutat amyloid precursor protein app
mutat let preferenti process app specif fragment term
peptid tendenc aggreg plaqu
peptid implic ad produc via proteolyt
cleavag app two proteas call -secretas inhibitor
proteas test ad therapeut faint hope
secretas inhibitor bace still use therapeut see eisai data
part hypothesi base clinic data anti-plaqu mab
work exampl aducanumab gantenerumab bind
primarili solubl insolubl aggreg seem work bapineuzumab
crenezumab report bind monomer aggreg
solanezumab ponezumab primarili select solubl monom
solanezumab extens test ad work signal tini
exhibit aducanumab affin greater ab multim
clinic data date
although old hat initi look plaqu remov data prime studi
quit shock data extrem clean plaqu patient brain
remov via deliveri antibodi system circul remov
dose time depend look exhibit make point pretti clear
smallish trial imag endpoint one data point seem fall place
one time data partli surpris although larg
quantiti aducanumab dose system believ
antibodi make mab reach
may make brain
exhibit aducanumab lead signific reduct amyloid-beta plaqu
competit asid small fraction dose aducanumab make brain
one featur make us worri long-term competit posit
approach aducanumab work aav deliveri approach voyag
uptak technolog denali via f-star may better deliveri approach
cognitive-funct data less pristin believ
prime studi also measur effect aducanumab multipl accept ad
endpoint includ mmse adas-cog cdr-sb readout much noisier
reach statist signific group addit dose
behav well term plaqu remov poorli cognit endpoint
done fair amount back analysi current best guess remain
overal given small size imperfect measur readout heterogen
ad find prime convinc may easi pleas find gener
idea remov precipit protein surfac neuron gener
exhibit cognit function readout prime suggest activ
aria characterist prime
safeti look good chronic dose fda approv seem reason
chronic dose therapeut asymptomat patient need quit safe
common relat advers event prime trial incid
headach fall amyloid-rel imag abnorm aria- edema remain
issu effect quit uncomfort patient possibl danger
although often trial
aria imag signal consist partner plaqu remov
aducanumab imag signal sometim accompani
symptom like dizzi occasion seriou symptom aria seem occur
earli dose often first month depend dose apo risk factor
ad attempt reduc aria titrat dose schedul seem
partial effect eisai due area- convinc fda stop
dose apo patient highest dose
detail aria prime
aria- observ patient dose aducanumab eight patient
one event case resolv assess mri week
onset patient aria- aria-h asymptomat
mild symptom aria- resolv mri patient
on-going patient time withdraw
silent aria ignor prime trial on-going trial patient
regularli undergo scan aria- event follow scan expens
commerci success aducanumab would probabl easier silent
asymptomat nearli event prime aria could ignor mean treat
patient scan patient symptom get scan look
aria start evolv trial test idea small trial
result probabl overs
data confirmatori
partner eisai develop second bind mab mani
attract bind properti aducanumab oligom monom
molecul much larger initi clinic trial aducanumab result
probabl less clear
seriou effort patient trial use novel endpoint
defin base readout previou trial design sensit
drug effect cognit function endpoint rate scale term
adcom composit score accept trial readout includ cdr-sb
element includ adas-cog element mmse element consist
fda guidanc adcom endpoint contain function compon
along cognit measur inclus base data previou
trial suggest potenti measur might sensit patient
earli ad mmse like prime studi patient screen plaqu
imag csf read use
exhibit piec adcom
dose data seem support activ trial
trial adapt design patient rout promis dose
group base earli adcom readout plaqu remov data load
patient dose group shown exhibit make clear top two
dose start receiv patient earli trial
big snafu one thing made trial difficult interpret decis
allow patient carri apo risk factor highest dose arm
trial decis made base aria signal occur
patient alreadi bi-weekli dose
rescu tri understand role imbal
explor data prime studi suggest patient apo
risk factor may get ad earlier becom symptomat dont progress
faster data present seem support claim effect
exclud patient apo risk factor small although dont
realli suggest differ
cognit data clear aducanumab
eisai releas data sever cognit behavior endpoint includ new
adcom endpoint clear taint mg/kg highest dose far
efficaci monthli dose often look better placebo bot
alway lower dose place eisai start elimin
figur
exhibit cognit function data trial
bace case antibodi help clear plaqu like
molecul inhibit function b-secretas form ab test
none approv therapeut includ bace inhibitor merck verubistat
test sever thousand early-ad prodrom ad
somewhat surpris along data eisai releas posit
bace data report studi first bace studi
show statist signific differ plaqu brain also suggest
delay clinic symptom declin exploratori endpoint includ cd-sob test
clinic dementia rate box
spinrazza aso pipelin
first jewel ioni collabor data focus effort
correct neurolog diseas effort modul gene express via antisens
oligonucleotid aso small synthet nucleic acid design reduc
protein express via interfer mrna translat turn protein
express allow express silent pseudo-gen level aso
expect compet gene therapi differ aso
probabl lifelong therapi rather gene therapi one-shot attempt correct
current second chanc howev aso doseabl level
correct adjust maxim patient benefit final aso good
tissu penetr featur shown exhibit spinraza aso
found throughout brain intrathec administr
biogen-ioni aso collabor probabl repres major program
pipelin on-going project mani program probabl high
risk approxim mono-gen human diseas lot
cost point view level aso activ biogen-ioni collabor
probabl daunt sound
first program earli mice may cheap
second manufactur point view aso expect
synthes purifi use similar step allow great streamlin
current success stori ioni collabor spinrazza hard
describ spiraza anyth one true miracl modern medicin
high risk approach modul gene express transform
uniformli fatal diseas less decad diseas spinal muscular atrophi
sma result ineffect copi gene low level smn
protein peopl second larg silent gene call produc
low level smn protein essenti irrelev presenc activ
howev sma patient without function smn protein come
gene level impair dictat copi number
gene word one copi doesnt make lot use smn protein
copi make enough approach normal function exhibit
exhibit sma diseas sever larg defin copi number
highli success launch competit derail ramp spinraza
nusinersen approv late base endear trial patient
infant onset sma drug receiv broad label beyond patient treat
trial like reflect good safeti profil irrevers damag occur
sma patient addit trial run nurtur trial young
pre-symptomat infant show correct subset patient near normal
high cost spinraza even hand patient move
revenu needl seem will offer unusu detail roll-out
spinrazsa reach billion cumul sale patient
therapi sale grew adult total increas came adult
give lot detail spinraza launch import metric us
sma patient adult even market
penetr forecast revenu billion
exhibit detail on-going spinraza launch
spine issu one linger issu spinraza intrathec deliveri drug
patient popul mani older patient type ii type sma kol
talk suggest issu manag drug common use
older patient current spinal fusion perform sma patient
growth plate fuse year old result type babi
issu addit equip requir perform intrathec inject patient
spinal fusion alreadi exist port surgic implant drill hole
equip approv use diseas includ cerebr
palsi futur fusion sma patient like occur less often due
effect treatment spinraza port left time surgeri
allow intrathec deliveri spinraza therapi
past on-going spinraza clinic studi
endear phase trial random double-blind
sham-procedur control studi includ infant diagnos
sma evalu mg dose spinraza interim analysi endear found
treat infant experienc statist signific improv motor mileston
compar treat versu base hammersmith infant
neurolog examin addit smaller percentag spinraza-tr infant
die compar untreat group base posit
interim result endear studi stop particip transit
shine open-label studi patient receiv spinraza shine
expect conclud februari
cherish phase random studi children
non-ambulatori later-onset sma age year old realiti
patient less due minimum hammersmith motor score entri criteria
full data present wca meet june slide avail
embrac phase double-blind studi evalu spinraza
safeti pharmacokinet patient didnt meet age criteria
endear cherish data expect
nurtur phase trial assess genet diagnos
pre-symptomat infant young patient six week old
given first dose first trial goal delay onset
exhibit nurtur data reveal true magic deliv spinraza
competit approv expect next six month
gene therapi develop avexi avx part
novarti nv rate therapi develop pivot trial stage
novarti acquir avx per share total billion cash
premium pre-announc stock price
seem logic acquir avexi manag alway critic
acquisit size base data dozen patient part
rational like exist intern aav program
program put clinic hold fda patient treat
manag comment recent sure path
forward program
comment elsewher note find lack involv
area gene therapi curiou given promis approach throughout
neurodegen diseas might expect compani activ
front signific transact
novarti recent announc accept bla grant
prioriti review set may decis data approv regulatori decis
japan expect slightli earlier europ slightli later part
announc name zolgensma reveal
launch mean spinraza billion dollar
question face right expect zolgensma launch
gradual probabl initi complic fact treatment
zolgensma spinraza support clinic data convers
comment mani patient trial also
approv expect seriou type form sma lethal earli life
base start trial recent report result
start trial zolgensma deliv intraven single-dos
infus patient month age patient alreadi symptomat
sever alreadi use ventil equip cohort dose cohort
receiv low dose cohort receiv higher dose data
trial higher dose patient includ
patient abl hold head erect second sit
without support second
patient abl sit without support second
patient abl sit without support second
patient abl stand alon abl walk assist
abl walk alon
patient cohort use non-invas ventil
niv baselin free daili niv use month follow-up
data quit close nurtur trial spinraza
major differ like driven slightli older patient start
addit insight clear individu patient function curv shown exhibit
exhibit avx singl patient respons curv compel
step gene therapi go forward next step zolgensma involv
manufactur deliveri gene therapi like also use older patient
type ii type sma system deliveri virion work
infant less like work older patient base develop blood brain
barrier amount materi requir system dose older patient may
beyond current manufactur capabl sanofi broad develop plan
indic exhibit see higher risk initi indic
system deliveri young type babi
exhibit develop timelin zolgensma
competit spinraza highli activ
help sma children surviv function vastli improv level howev neither
look truli cur involv complex deliveri result risdiplam oral
gene-express modifi rate intrigu
gener data bear watch program partner roch
trial call jewelfish roche/ptc demonstr improv amount
sma protein patient previous treat sma drug shown exhibit
level smn protein induc treatment similar protein
level seen type type ii sma patient
exhibit increas product smn protein treatment
recent updat part firefish studi day treatment
infant abl sit without support includ three achiev
unassist sit addit babi remain aliv
part sunfish studi type sma patient patient
treat risdiplam least one year achiev median increas motor
function measur point versu baselin typic patient
type sma declin point per year final median smn protein
level increas greater sustain month
expand pipelin deal spiraza deal sign mani year ago
probabl good deal base deal two compani start
addit collabor enter clinic recent
compani expand collabor much much larger deal
multipl target detail program includ
access technolog neurolog diseas
fair market valu ioni stock
drug success get market drug
success get market
tier royalti mid -teen
relationship littl difficult pars separ deal partli
everyth go recent deal disclos howev overal
compani may work mani target
lead pipelin asset genet al
aso biogen ioni pipelin becom materi genet
form al rare fatal neurodegen diseas character motor
neuron loss brain spinal cord respons control voluntari
muscl movement al devast neurodegen diseas gener
rapidli progress common symptom includ degener neuron spinal
cord area brain result pronounc muscl atrophi result
loss abil walk speak long-tim face diseas lou
gehrig yanke cleanup hitter hit third took line-up
hit poorli die diseas within year stephan hawk
anoth well-known suffer black hole al consid remark
durat diseas symptomat decad
small popul mutat superoxid dismutas gene gene believ
respons famili case al sporad case total
recent opt program made one-tim million payment
ioni futur payment includ potenti post-licens mileston payment
million royalti low mid-teen ww sale respons
develop manufactur commerci
opt base studi achiev proof-of-biolog proof-of-
concept highest dose test treatment
three month period result statist signific lower protein level
cerebrospin fluid numer trend toward slow clinic
declin measur al function rate scale-revis compar
exhibit trial
gene therapi well much like sma al result toxic
target gene therapi voyag therapeut buy gener
interest data non-human primat nhp overal expect al much
like sma one-tim conveni gene therapi balanc
dose flexibl excel tissu penetr aso al gene therapi
consid difficult larg deliveri area requir fulli treat symptom
voyag report knockdown multipl human cell lead
construct reduc toxic gene product non-human primat report
therapi well toler
midlin shift data suggest activ
efficaci lhi like approv drug could get use
extrem tough indic care patient select
matter past trial
stroke fit model begun fairli recent push stroke base
two acquisit area make sens us like much neurosci
mechan damag ischem stroke imparti understood imag
employ monitor damag occur two current program biogen
extend window clot bust unlik activas
directli convert plasminogen plasmin mechan high chanc
caus system bleed rather tm act area clot
activ chang conform plasminogen increas fibrin bind
facilit activ endogen tpa drug also thought
inhibit solubl epoxid hydrolas reduc product pro-inflammatori
mediat vasoconstrict breakdown blood brain barrier
trial on-going data expect
seriou stroke biogen target seriou stroke
gener involv occlus middl cerebr arteri perfus larg
central region brain
infarct lhi repres ischem stroke gener
involv sever edema level deform brain within skull
herniat data program interest enough detail
appear lancet neurolog primari endpoint met trial
on-going cover spa
exhibit lhi patient cerebr edema midlin shift
signific market approxim million stroke occur year
addit million occurr europ japan annual two
type stroke hemorrhag blood vessel ruptur ischem stroke vessel
blockag current focus ischem stroke repres nearli
total current two major stroke program base
visit compani lower risk gener appreci program
could also pivot trial next believ
mortal rate lhi high estim rang wherea
mortal rate overal stroke closer approxim
larg hemispher infarct case europ japan per year
poor soc fda-approv ischem stroke activas thrombolyt
approv activas tissu plasminogen activ tpa clot buster
fda label must administ within three hour symptom onset approv
base two posit placebo-control double-blind studi acut ischem
stroke patient howev sever trial posit trial activas
administ within three hour symptom onset
first trial primari endpoint improv nation institut
stroke scale nihss hour second trial studi activas three month
bi score mr score glasgow outcom scale score nihss
score endpoint statist signific exhibit
exhibit activas data three month studi
ischemia hypoxia traumat condit result
mechan stop ion driven edema intraven glyburid work
inhibit channel reduc stroke relat brain swell
specif channel believ trigger atp deplet open
microvascular permeabl endotheli cell lead cerebr edema
clinic readout test phase ii random doubl blind
placebo control studi patient primari dataset games-rp overal
believ data exhibit suggest strongli reduc brain swell
comment believ drug ever shown reduc
midlin shift gross indic brain swell gross distens often
catastroph shift mm gener fatal addit chang
midlin shift games-rp correl mortal mr
exhibit reduc midlin shift lhi patient
victim endpoint games-rp trial primari endpoint fraction
patient modifi rankin score mr without decompress
craniotomi dc surgic approach reduc pressur trial clearli miss
howev result appear significantli confound dc rate
high trial retrospect often occur patient well enough
warrant surgic intervent importantli chang midlin shift
marker bbb integr convincingli posit day mortal rate
disabl rate day exhibit
exhibit games-rp enough posit endpoint warrant test
phase trial design acquir phase readi asset remedi
pivot trial list clinicaltri gov howev studi
open begun trial cover spa
agreement fda
exhibit trial design cover spa agreement
ms busi balanc nice
much market share mab take ms novarti mab
good better ocrelizumab would royalti
ozanimod import ms drug tend think partli base
celgen new ms arena addit drug like get class
new mmf prodrug diroximel fumar interest first
potenti approv base submiss involv
bioequival safeti second trial read design
tecfidera ip issu take center stage move still find
curiou paid allow court destroy forward pharma
forward rate patent seem extend dose protect tecfidera
ipr challeng seem low risk given level scrutini
patent seen
ms-focus initi matter could make tysabri safer
interferon easier use lead anyth substanti tysabri seem
like program matter patient love drug activ
formula dose test could drive maintain sale
exhibit tysabri highli activ pml risk curtail use
remyelin interest arent sure although sound good might
help inflammatori piec ms leav less well understood
process axon cell death untouch would provid essenti
addit benefit inflammation-freez drug like ocrelizumab mani
year know
right ms franchis happili throw cash come fairli
tens period ms franchis result introduct
mab ocrelizumab ocrevu antibodi probabl effect ms
treatment seen date although tysabri close featur attract safeti
profil everi six month dose
exhibit tecfidera tysabri held ocrevu
overview ms market dynam provid opportun improv
ms market eclips billion mark world-wide biogen
estim remain penetr patient
receiv treatment number probabl somewhat mislead mani
world resid arent potenti user per year therapeut anytim
soon howev global compani market open like
readi compani build commerci oper overal ms
market grow mid-singl percentag world-wide
market dynam perhap relev stori market
dynam patient receiv treatment year fairli
dynam market see new patient annual along
patient switch switch probabl fall two form patient switch
rapidli side effect reason gi intoler tecfidera also
patient treatment failur drug prompt switch
power drug along line work develop serum
neurofila earli marker diseas worsen marker
prove inform seem like drive switch especi
ms pipelin featur full gamut risk beyond line extens
novel pipelin ms treatment includ two remyelin candid
altern prodrug mmf design reduc gi toxic
repair damag ms remyelin program includ anti-lingo
molecul opicinumab small molecul asset resurrect base
insight made explor opicinumab program remain
high risk eye obvious extrem valuabl success
remyelin believ activ suppress activ
peripher nerv activ therapeut might need stop action
make myelin surfac neuron doesnt automat equat improv
nerv function far know data show remyelin present
possibl know function
ms believ involv two process inflammatori process remov
myelin nerv surfac possibl equat relaps remit form
slow death neuron possibl progress form drug like ocrelizumab
tysabri essenti stop inflammatori form clear much
said still like approach lead asset opicinumab
second trial second small molecul enter clinic
synergi ran trial call synergi rrm spm
stabl interferon therapi drug found safe hit origin
primari endpoint howev post hoc analysi suggest treatment effect
highest dose group includ numer improv lower upper limb
function energi mental health overal physic function week
week treatment effect deem consist
improv observ clinic brain imag endpoint synergi
aphin second studi rrm patient stabl dmt
primari endpoint studi overal respons score or integr
measur improv worsen disabl time novel
featur trial rel synergi includ enrich patient
demyelin intact exon approach requir two type mri
imag see two desir properti patient neuron turn
reason process eye
compani comment two key issu screen process
failur rate reliabl sampl process within given
person word detail analysi one plaqu associ neuron
diagnost patient overal mani plaqu neuron need
oral demyelin drug decid pursu base
rapid progress opicinumab program enrol seven month faster
project dont know much program get small molecul
brain certainli seem easier deliv antibodi
gi toxic issu tecfidera result patient start drug
switch rapidli work hard solv issu focus
reduc gi discontinu sourc growth tecfidera franchis amus
true anoth shot solv problem acquir vumer
eye deal look good parti receiv
million up-front million fda approv end royalti
addit help sell new ms drug extrem entrench
market chanc fix real issu tecfidera gi intoler
lead discontinu probabl steer mani other away
start drug
vumer file pathway day ago
reluct discuss differ tecfidera vumer hint
differ gi
intoler also rate
discontinu gi intoler trial number seem much
lower tecfidera discontinu real world report
although apple-to-appl comparison
modest worri thing worri us vumer program first
approach drug design differ refer drug
assum fda buy issu weve seen
approach work past may rais bar precis pharmacokinet
equival activ moieti
second real differ leav group gi issu activ moieti
might remain take comfort involv long
histori novel api formul
tau ad ad diseas character two protein aggreg ab
plaqu target aducanumab also tangl protein tau highli
phosphoryl state structur similar contain amyloid fold seen
toxic protein aggreg mani kind includ amyloid- tau -synuclein
aggreg tau protein implic ad progress function protein
solubl form serv stabil microtubul normal neuron tau promot
microtubul stabil bind tubulin microtubul bind domain
compris four imperfect repeat tau becom overli phosphoryl
aggreg aggreg kill neuron two tau-focus antibodi
program clinic develop data earli think
program although earli might interest due develop pet
probe visual tau aggreg
fibrosi program fibrosi sinc compani acquir stromedix
lead candid deal involv million up-front
conting valu payment base achiev certain develop
approv mileston across multipl
human
monoclon antibodi block function integrin result reduc
signal tgf- pathway ipf patient review tgf-beta pathway
gener accept main driver fibrot diseas enter
phase trial patient idiopath pulmonari fibrosi ipf debilit
almost uniformli fatal diseas patient experi progress difficulti
breath due fibrosi scar lung soc ipf base two drug
view limit efficaci howev approv statu suggest pivot trial
combin
biosimilar busi thrill
constantli use broad expertis pop new area hemophilia
exampl biosimilar current exampl current sale
annual manag guid doubl revenu
exhibit sale ramp biosimilar busi
thoma shrader harrison incom multipl sclerosistecfidera zinbryta- alzheim saducanumab risk adjust smaspinraza- risk adjust flixabri- biosimilars- product revenu therapeut program royalti total research sell gener amort acq intang fair valu adj contig collabor profit sharing- acquir in-process research development- tecfidera litig settlement licens charges- restructur total oper interest incom expens incom incom tax equiti loss investe net net incom non-controlling net incom total non- non- net incom ep non- ep basic share dilut share
thoma shrader harrison balanc asset cash market account due unconsolid joint current total current market properti equip intang asset defer tax assets- invest total liabil stockhold equitycurr liabil note payabl line tax account accru expens total current note payabl long-term der tax long-term total equiti prefer stockcommon accumul comprehens incom retain treasuri stock total biogen shareshold non-controlling total total liabil sharehold
thoma shrader harrison flow oper activ net incom depreci acquir in-process research share base conting defer account accru expens current current tax liabil tax due unconsolid joint net cash provid oper flow invest activ proce sale matur market purchas market acquisit tysabri rights- conting consider relat fumapharm ag acquisit purchas properti plant net cash provid invest flow financ activ purchas treasuri proce stock-bas compens excess tax benefit stock proce repay net cash provid financ net increas decreas cash cash effect exchang equival begin cash equival end
btig cover compani mention report
appendix analyst certif import disclosur
